These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 26123846)

  • 1. Opening the window: Ischemic postconditioning reduces the hyperemic response of delayed tissue plasminogen activator and extends its therapeutic time window in an embolic stroke model.
    Esmaeeli-Nadimi A; Kennedy D; Allahtavakoli M
    Eur J Pharmacol; 2015 Oct; 764():55-62. PubMed ID: 26123846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transient brain hypothermia reduces the reperfusion injury of delayed tissue plasminogen activator and extends its therapeutic time window in a focal embolic stroke model.
    Zarisfi M; Allahtavakoli F; Hassanipour M; Khaksari M; Rezazadeh H; Allahtavakoli M; Taghavi MM
    Brain Res Bull; 2017 Sep; 134():85-90. PubMed ID: 28710023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Whole body hypothermia extends tissue plasminogen activator treatment window in the rat model of embolic stroke.
    Hassanipour M; Zarisfi M; Ehsani V; Allahtavakoli M
    Life Sci; 2020 Sep; 256():117450. PubMed ID: 32087233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ischemic post-conditioning is neuroprotective even at delayed tPA administration after embolic stroke in female rats.
    Mohammadi M; Mobini M; Mashayekhi F; Allahtavakoli M; Kaeidi A; Hassanshahi J; Shamsizadeh A; Hakimizadeh E; Hassanipour M
    Iran J Basic Med Sci; 2021 Dec; 24(12):1676-1682. PubMed ID: 35432799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant treatment with neuroserpin increases the therapeutic window for tissue-type plasminogen activator administration in a rat model of embolic stroke.
    Zhang Z; Zhang L; Yepes M; Jiang Q; Li Q; Arniego P; Coleman TA; Lawrence DA; Chopp M
    Circulation; 2002 Aug; 106(6):740-5. PubMed ID: 12163437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delayed postconditioning protects against focal ischemic brain injury in rats.
    Ren C; Gao X; Niu G; Yan Z; Chen X; Zhao H
    PLoS One; 2008; 3(12):e3851. PubMed ID: 19066627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebral endothelial cell-derived small extracellular vesicles enhance neurovascular function and neurological recovery in rat acute ischemic stroke models of mechanical thrombectomy and embolic stroke treatment with tPA.
    Li C; Wang C; Zhang Y; Alsrouji OK; Chebl AB; Ding G; Jiang Q; Mayer SA; Lu M; Kole MK; Marin HL; Zhang L; Chopp M; Zhang ZG
    J Cereb Blood Flow Metab; 2021 Aug; 41(8):2090-2104. PubMed ID: 33557693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Normobaric hyperoxia reduces the neurovascular complications associated with delayed tissue plasminogen activator treatment in a rat model of focal cerebral ischemia.
    Liu W; Hendren J; Qin XJ; Liu KJ
    Stroke; 2009 Jul; 40(7):2526-31. PubMed ID: 19478225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of tissue plasminogen activator on cerebral microvessels of rats during focal cerebral ischemia and reperfusion.
    Yang DY; Pan HC; Chen CJ; Cheng FC; Wang YC
    Neurol Res; 2007 Apr; 29(3):274-82. PubMed ID: 17509227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination treatment with low-dose Niaspan and tissue plasminogen activator provides neuroprotection after embolic stroke in rats.
    Shehadah A; Chen J; Cui Y; Zhang L; Roberts C; Lu M; Chopp M
    J Neurol Sci; 2011 Oct; 309(1-2):96-101. PubMed ID: 21802695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Normobaric hyperoxia slows blood-brain barrier damage and expands the therapeutic time window for tissue-type plasminogen activator treatment in cerebral ischemia.
    Liang J; Qi Z; Liu W; Wang P; Shi W; Dong W; Ji X; Luo Y; Liu KJ
    Stroke; 2015 May; 46(5):1344-1351. PubMed ID: 25804925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vepoloxamer Enhances Fibrinolysis of tPA (Tissue-Type Plasminogen Activator) on Acute Ischemic Stroke.
    Wang C; Huang R; Li C; Lu M; Emanuele M; Zhang ZG; Chopp M; Zhang L
    Stroke; 2019 Dec; 50(12):3600-3608. PubMed ID: 31587657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interrupting reperfusion as a stroke therapy: ischemic postconditioning reduces infarct size after focal ischemia in rats.
    Zhao H; Sapolsky RM; Steinberg GK
    J Cereb Blood Flow Metab; 2006 Sep; 26(9):1114-21. PubMed ID: 16736038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant treatment with a glycoprotein IIb/IIIa receptor inhibitor increases the therapeutic window for low-dose tissue plasminogen activator administration in a rat model of embolic stroke.
    Zhang L; Zhang ZG; Zhang R; Morris D; Lu M; Coller BS; Chopp M
    Circulation; 2003 Jun; 107(22):2837-43. PubMed ID: 12756151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early administration of pyrrolidine dithiocarbamate extends the therapeutic time window of tissue plasminogen activator in a male rat model of embolic stroke.
    Wang Z; Shan W; Cao J; Wintermark M; Huang W; Zuo Z
    J Neurosci Res; 2018 Mar; 96(3):449-458. PubMed ID: 28976017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. THR-18, a 18-mer peptide derived from PAI-1, is neuroprotective and improves thrombolysis by tPA in rat stroke models.
    Krakovsky M; Polianski V; Nimrod A; Higazi A; Leker RR; Lamensdorf I
    Neurol Res; 2011 Nov; 33(9):983-90. PubMed ID: 22081002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ascorbic Acid Reduces the Adverse Effects of Delayed Administration of Tissue Plasminogen Activator in a Rat Stroke Model.
    Allahtavakoli M; Amin F; Esmaeeli-Nadimi A; Shamsizadeh A; Kazemi-Arababadi M; Kennedy D
    Basic Clin Pharmacol Toxicol; 2015 Nov; 117(5):335-9. PubMed ID: 25899606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atorvastatin extends the therapeutic window for tPA to 6 h after the onset of embolic stroke in rats.
    Zhang L; Chopp M; Jia L; Cui Y; Lu M; Zhang ZG
    J Cereb Blood Flow Metab; 2009 Nov; 29(11):1816-24. PubMed ID: 19638998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Candesartan reduces the hemorrhage associated with delayed tissue plasminogen activator treatment in rat embolic stroke.
    Ishrat T; Pillai B; Ergul A; Hafez S; Fagan SC
    Neurochem Res; 2013 Dec; 38(12):2668-77. PubMed ID: 24194350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of ML351 and tissue plasminogen activator combination therapy in a rat model of focal embolic stroke.
    Cheng G; Zhao W; Xin Y; Huang G; Liu Y; Li Z; Zhan M; Li Y; Lu L; van Leyen K; Liu Y
    J Neurochem; 2021 May; 157(3):586-598. PubMed ID: 33481248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.